These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36017299)

  • 1. Can Phosphodiesterase 4 Inhibitor Therapy Be Used in Respiratory Diseases Other Than Chronic Obstructive Pulmonary Disease?
    Goonathilake MR; Waqar S; George S; Jean-Baptiste W; Yusuf Ali A; Inyang B; Koshy FS; George K; Poudel P; Chalasani R; Mohammed L
    Cureus; 2022 Jul; 14(7):e27132. PubMed ID: 36017299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease.
    Facchinetti F; Civelli M; Singh D; Papi A; Emirova A; Govoni M
    Front Pharmacol; 2021; 12():740803. PubMed ID: 34887752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases.
    Kawamatawong T
    Front Pharmacol; 2021; 12():518345. PubMed ID: 34434103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases.
    Phillips JE
    Front Pharmacol; 2020; 11():259. PubMed ID: 32226383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials.
    Cazzola M; Page C; Calzetta L; Singh D; Rogliani P; Matera MG
    Immunotherapy; 2023 Dec; 15(18):1511-1519. PubMed ID: 37779474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.
    Abbott-Banner KH; Page CP
    Basic Clin Pharmacol Toxicol; 2014 May; 114(5):365-76. PubMed ID: 24517491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2013 Nov; (11):CD002309. PubMed ID: 24190161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Inhibition of Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases: Current and Future Evidences.
    Contreras S; Milara J; Morcillo E; Cortijo J
    Curr Pharm Des; 2017; 23(14):2073-2083. PubMed ID: 28201975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
    Lipworth BJ
    Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases.
    Kawamatawong T
    J Thorac Dis; 2017 Apr; 9(4):1144-1154. PubMed ID: 28523172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review.
    Martin C; Burgel PR; Roche N
    Int J Chron Obstruct Pulmon Dis; 2021; 16():2363-2373. PubMed ID: 34429594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS.
    Bodkhe S; Nikam M; Sherje AP; Khan T; Suvarna V; Patel K
    Int Immunopharmacol; 2020 Nov; 88():106906. PubMed ID: 33182057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective PDE inhibitors as novel treatments for respiratory diseases.
    Page CP; Spina D
    Curr Opin Pharmacol; 2012 Jun; 12(3):275-86. PubMed ID: 22497841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
    Page CP; Spina D
    Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of phosphodiesterase 4 inhibitors in patients with asthma: A systematic review and meta-analysis.
    Luo J; Yang L; Yang J; Yang D; Liu BC; Liu D; Liang BM; Liu CT
    Respirology; 2018 May; 23(5):467-477. PubMed ID: 29502338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
    Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
    Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superiority of combined phosphodiesterase PDE3/PDE4 inhibition over PDE4 inhibition alone on glucocorticoid- and long-acting β2-adrenoceptor agonist-induced gene expression in human airway epithelial cells.
    BinMahfouz H; Borthakur B; Yan D; George T; Giembycz MA; Newton R
    Mol Pharmacol; 2015 Jan; 87(1):64-76. PubMed ID: 25324049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.